Quantitative enzyme radioautography with 3H-Ro 41-1049 and 3H-Ro 19- 6327 in vitro: localization and abundance of MAO-A and MAO-B in rat CNS, peripheral organs, and human brain

Monoamine oxidases A and B (MAO-A and MAO-B) oxidatively deaminate neurotransmitter and xenobiotic amines. Since the cellular localization of the isoenzymes in the CNS and peripheral organs determines to a large extent which substrate has access to which isoenzyme, knowledge of their tissue distribution and cellular localization is essential. Here we describe how reversible and selective inhibitors of MAO-A and MAO-B [Ro 41–1049 and Ro 19–6327 (lazabemide), respectively] can be used, as tritiated radioligands, to map the distribution and abundance of the enzymes in microscopic regions of the rat CNS and peripheral organs, and human brain by quantitative enzyme radioautography. The in vitro binding characteristics of both radiolabeled inhibitors revealed them to be selective, high-affinity ligands for the respective enzymes. KD and Bmax values for 3H-Ro 41–1049 in rat cerebral cortex were 10.7 nM and 7.38 pmol/mg protein, respectively, and for 3H-Ro 19–6327 were 18.4 nM and 3.45 pmol/mg protein, respectively. In accordance with their potencies as enzyme inhibitors, binding to MAO-A and MAO-B was competitively inhibited by clorgyline (IC50 = 1.4 nM) and L-deprenyl (selegiline; IC50 = 8.0 nM), respectively. The capacities of various rat and human tissues to bind the radioligands correlated extremely well with their corresponding enzyme activities. As revealed by the respective binding assays, the distribution and abundance of MAO-A and MAO-B in the tissues investigated differed markedly. MAO-A was most abundant in the locus coeruleus, paraventricular thalamus, bed nucleus of the stria terminalis, median habenular nucleus, ventromedial hypothalamus, raphe nuclei, solitary tract nucleus, inferior olives, interpeduncular nucleus, claustrum, and numerous peripheral tissues, including liver, vas deferens, heart, superior cervical ganglion, and exocrine and endocrine pancreas. In contrast, MAO-B was most abundant in the ependyma, circumventricular organs, olfactory nerve layer, periventricular hypothalamus, cingulum, hippocampal formation, raphe nuclei, paraventricular thalamus, mammillary nuclei, cerebellar Bergmann glia cells, liver, posterior pituitary, renal tubules, and endocrine pancreas. The cellular localization of the isoenzymes in both rat and human brain differs markedly and does not reflect the distribution of the presumed natural substrates, for example, absence of MAO-A in serotoninergic neurons. Indeed, the present evidence suggests that, whereas MAO-A is found in noradrenergic and adrenergic neurons, MAO-B occurs in astrocytes, serotoninergic neurons, as well as ventricular cells, including most circumventricular organs. The physiological roles of the enzymes are discussed in the light of these findings, some of which were unexpected.(ABSTRACT TRUNCATED AT 400 WORDS)

[1]  J. Shih,et al.  Human monoamine oxidase A and B genes exhibit identical exon-intron organization. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[2]  J. Pintar,et al.  Guinea pig pancreatic ganglia: Projections, transmitter content, and the type‐specific localization of monoamine oxidase , 1991, The Journal of comparative neurology.

[3]  M. Pawlik,et al.  [3H]Harman Binding Experiments. I: A Reversible and Selective Radioligand for Monoamine Oxidase Subtype A in the CNS of the Rat , 1991, Journal of neurochemistry.

[4]  M. Youdim,et al.  New directions in monoamine oxidase A and B selective inhibitors and substrates. , 1991, Biochemical pharmacology.

[5]  W. Burkard,et al.  Some basic aspects of reversible inhibitors of monoamine oxidase‐A , 1990, Acta psychiatrica Scandinavica. Supplementum.

[6]  C. Zahnow,et al.  Localization of histidine decarboxylase mRNA in rat brain , 1990, Molecular and Cellular Neuroscience.

[7]  R. Schmidt-Kastner,et al.  Immunohistochemistry of glial fibrillary acidic protein, vimentin and S-100 protein for study of astrocytes in hippocampus of rat. , 1990, Journal of chemical neuroanatomy.

[8]  H. Heinsen,et al.  Demonstration of monoamine oxidase-A and -B in the human brainstem by a histochemical technique , 1989, Neuroscience.

[9]  T. Maeda,et al.  Monoamine oxidase-containing nerve fibers in the major cerebral arteries of rats , 1989, Brain Research.

[10]  J. Langston,et al.  The effect of deprenyl (selegiline) on the natural history of Parkinson's disease. , 1989, Science.

[11]  T. Maeda,et al.  Type B monoamine‐oxidase‐containing cells and fibers in the cat hypothalamus demonstrated by an improved enzyme histochemical method , 1989, The Journal of comparative neurology.

[12]  M. Strolin Benedetti,et al.  Monoamine oxidase, brain ageing and degenerative diseases. , 1989, Biochemical pharmacology.

[13]  T. Halonen,et al.  Dopaminergic system and monoamine oxidase-B Activity in Alzheimer's disease , 1988, Neurobiology of Aging.

[14]  P. Seeburg,et al.  cDNA cloning of human liver monoamine oxidase A and B: molecular basis of differences in enzymatic properties. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[15]  R. M. Rose,et al.  Localization of distinct monoamine oxidase a and monoamine oxidase b cell populations in human brainstem , 1988, Neuroscience.

[16]  M. Rizzo,et al.  Blindsight: A case study and implications by L. Weiskrantz, Oxford University Press, 1986. £ 19.50 (viii + 187 pages) ISBN 9 18 852129 4 , 1987, Trends in Neurosciences.

[17]  P. Reiner,et al.  Coupled intracellular horseradish peroxidase-monoamine oxidase histochemistry: description of the technique and its application to the study of physiologically identified tuberomammillary neurons , 1987, Journal of Neuroscience Methods.

[18]  T. Maeda,et al.  Distribution of two types of monoamine oxidase-containing neurons in the cat medulla oblongata demonstrated by an improved histochemical method , 1987, Neuroscience.

[19]  T. Maeda,et al.  Topographic atlas of monoamine oxidase-containing neurons in the rat brain studied by an improved histochemical method , 1986, Neuroscience.

[20]  S. Vincent,et al.  Histochemistry of MPTP oxidation in the rat brain: Sites of synthesis of the parkinsonism-inducing toxin MPP+ , 1986, Neuroscience Letters.

[21]  B. Parsons,et al.  Similar distribution of monoamine oxidase (MAO) and parkinsonian toxin (MPTP) binding sites in human brain , 1985, Neurology.

[22]  H. Kimura,et al.  Cortical projections of monoamine oxidase-containing neurons from the posterior hypothalamus in the rat , 1984, Neuroscience Letters.

[23]  G. Uhl,et al.  Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6 -tetrahydropyridine: characterization and localization of receptor binding sites in rat and human brain. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[24]  B. Winblad,et al.  Biochemical changes in Dementia disorders of Alzheimer type (AD/SDAT) , 1983, Neurobiology of Aging.

[25]  X. Breakefield,et al.  Specificity of antisera prepared against pure bovine MAO-B , 1983, Brain Research.

[26]  W. Vogel,et al.  Monoamine oxidase in four rat and human tissues. , 1981, Biochemical medicine.

[27]  J. P. Johnston Some observations upon a new inhibitor of monoamine oxidase in brain tissue. , 1968, Biochemical pharmacology.

[28]  R. Pearson,et al.  The Human Nervous System. Basic Elements of Structure and Function , 1967, The Yale Journal of Biology and Medicine.

[29]  G. Glenner,et al.  THE HISTOCHEMICAL DEMONSTRATION OF MONOAMINE OXIDASE ACTIVITY BY TETRAZOLIUM SALTS , 1957, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[30]  H. Blaschko,et al.  The inactivation of adrenaline , 1937, The Journal of physiology.

[31]  W. Haefely,et al.  Ro 19-6327, a reversible and highly selective monoamine, oxidase B inhibitor: a novel tool to explore the MAO-B function in humans. , 1990, Advances in neurology.

[32]  M. da Prada,et al.  Molecular neuroanatomy of MAO-A and MAO-B. , 1990, Journal of neural transmission. Supplementum.

[33]  L. Oreland,et al.  Visualization of brain monoamine oxidase B (MAO-B) in dementia of Alzheimer's type by means of large cryosection autoradiography: a pilot study. , 1990, Journal of neural transmission. Supplementum.

[34]  A. Cesura,et al.  From moclobemide to Ro 19-6327 and Ro 41-1049: the development of a new class of reversible, selective MAO-A and MAO-B inhibitors. , 1990, Journal of neural transmission. Supplementum.

[35]  R. Heikkila,et al.  Monoamine oxidase and the bioactivation of MPTP and related neurotoxins: relevance to DATATOP. , 1990, Journal of neural transmission. Supplementum.

[36]  T. Kuwahara,et al.  Primary structure of rat monoamine oxidase A deduced from cDNA and its expression in rat tissues. , 1990, Agricultural and biological chemistry.

[37]  P. Riederer,et al.  The role of MAO in dopaminergic transmission. , 1990, Advances in neurology.

[38]  U. Trendelenburg The interaction of transport mechanisms and intracellular enzymes in metabolizing systems. , 1990, Journal of neural transmission. Supplementum.

[39]  W. Burkard,et al.  Pharmacological profile of moclobemide, a short-acting and reversible inhibitor of monoamine oxidase type A. , 1989, The Journal of pharmacology and experimental therapeutics.

[40]  K. Tipton,et al.  Interactions of monoamine oxidase with substrates and inhibitors , 1989, Medicinal research reviews.

[41]  DATATOP: a multicenter controlled clinical trial in early Parkinson's disease. Parkinson Study Group. , 1989, Archives of neurology.

[42]  H. Heinsen,et al.  Histochemistry of MAO subtypes in the brainstem of humans: a relation to the radical hypothesis of Parkinson’s disease? , 1989 .

[43]  R. Kettler,et al.  Platelet MAO-B activity in humans and stumptail monkeys: in vivo effects of the reversible MAO-B inhibitor Ro 19-6327 , 1989 .

[44]  W. Burkard,et al.  Neurochemical profile of moclobemide, a short-acting and reversible inhibitor of monoamine oxidase type A. , 1989, The Journal of pharmacology and experimental therapeutics.

[45]  W. Burkard,et al.  Preclinical profiles of the novel reversible MAO-A inhibitors, moclobemide and brofaromine, in comparison with irreversible MAO inhibitors. , 1989, Journal of neural transmission. Supplementum.

[46]  Anthony E. Lang,et al.  Effect of deprenyl on the progression of disability in early Parkinson's disease. , 1989, The New England journal of medicine.

[47]  A. Cesura,et al.  Quantitative enzyme radioautography with [3H]Ro 19-6327: Localization of MAO-B in rat CNS, peripheral organs and human brain , 1988 .

[48]  A. Juorio Brain Trace Amines: Mapping Studies and Effects of Mesencephalic Lesions , 1988 .

[49]  T. Maeda,et al.  An improved coupled peroxidatic oxidation method of MAO histochemistry for neuroanatomical research at light and electron microscopic levels. , 1987, Cellular and molecular biology.

[50]  M. Sandler,et al.  Monoamine Oxidase and The Brain , 1987, Reviews in the neurosciences.

[51]  R. Denney,et al.  An update on the identity crisis of monoamine oxidase: new and old evidence for the independence of MAO A and B. , 1985, Pharmacology & therapeutics.

[52]  H. Steinbusch,et al.  Serotonin-immunoreactive neurons and their projections in the CNS , 1984 .

[53]  T. Maeda,et al.  HISTOCHEMISTRY OF THE MAGNOCELLULAR NEURONS IN THE POSTERIOR HYPOTHALAMUS, WITH SPECIAL REFERENCE TO MAO ACTIVITY AND ABILITY OF 5HTP UPTAKE AND DECARBOXYLATION , 1984 .

[54]  T. Hökfelt,et al.  Classical transmitters in the CNS , 1984 .

[55]  T. Maeda,et al.  Histochemical demonstration for monoamine oxidase (MAO) by a new coupled peroxidation method. , 1983, Cellular and molecular biology.

[56]  K. Magyar,et al.  Some puzzling pharmacological effects of monoamine oxidase inhibitors. , 1972, Advances in biochemical psychopharmacology.